Navigation Links
Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
Date:7/9/2013

BURLINGTON, Mass., July 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European oncologists indicate that overall survival is the factor that most influences their prescribing decisions for unresectable malignant melanoma, and that increased overall survival is associated with the highest level of unmet need. Interviewed thought-leaders are optimistic that Bristol-Myers Squibb/Ono Pharmaceuticals' nivolumab and GlaxoSmithKline's Tafinlar plus GlaxoSmithKline's Mekinist, in particular, will show advantages over sales-leading ipilimumab (Bristol-Myers Squibb's Yervoy) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled As Vemurafenib and Ipilimumab Gain Traction in the Market, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? finds that surveyed U.S managed care organization (MCO) pharmacy directors demand that emerging therapies provide significant improvements in overall survival over vemurafenib (Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf) to justify their cost and secure reimbursement. Vemurafenib is the premium-priced standard-of-care in unresectable malignant melanoma patients harboring the V600 BRAF mutation. Notably, a third of surveyed payers would not reimburse a new therapy priced the same as vemurafenib or higher that offers a six-month improvement in overall survival over vemurafenib, citing insufficient overall clinical benefit as one of the key reasons for not granting reimbursement.

The report also finds that surveyed U.S. and European oncologists identified hematological toxicity as the safety and tolerability attribute that is most important when making prescribing decisions in unresectable malignant melanoma, thus indicating the persisting high level of unmet need for therapies with a more favorable hematological profile.

"Despite the improvements effected by vemurafenib and ipilimumab on patient overall survival in unresectable malignant melanoma, our survey results suggest that both physicians and MCO pharmacy directors have high expectations of the requirements of emerging therapies to further extend survival," said Decision Resources Business Insights Analyst Samuel Mentzer, M.Sc. "Early-stage clinical data suggest that Tafinlar in combination with Mekinist and nivolumab have the potential to gain a competitive edge over ipilimumab and vemurafenib if they can replicate these promising results in their ongoing Phase III trials."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen
4. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
5. Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
6. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
7. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
8. Effectively Bringing Fixed Dose Combination Products to Market to Maintain Growth and Pipelines
9. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
10. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
11. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... May 27, 2016 Amarantus BioScience Holdings, ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... presenting at two upcoming investor conferences: SeeThru Equity ... Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... ... ... MadgeTech will be showcasing its line of data logging products , ... MadgeTech headquarters. With products sold in more than 100 countries around the world, MadgeTech ... , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data loggers around ...
Breaking Medicine News(10 mins):